Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis
暂无分享,去创建一个
[1] K. Thorlund,et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] K. Tsukiyama-Kohara. Role of Oxidative Stress in Hepatocarcinogenesis Induced by Hepatitis C Virus , 2012, International journal of molecular sciences.
[3] M. Arafa,et al. Persistent Oxidative Stress in Patients with Chronic Active Hepatitis-C Infection After Antiviral Therapy Failure , 2012, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.
[4] A. Craxì,et al. Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[5] H. Yen,et al. Decreased mitochondrial deoxyribonucleic acid and increased oxidative damage in chronic hepatitis C. , 2012, World journal of gastroenterology.
[6] Zhiliang Gao,et al. Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype , 2012, Virology Journal.
[7] J. Dias,et al. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. , 2012, Gastroenterologia y hepatologia.
[8] Mohammad Pessarakli,et al. Reactive Oxygen Species, Oxidative Damage, and Antioxidative Defense Mechanism in Plants under Stressful Conditions , 2012 .
[9] L. Vieira,et al. Reactive Oxygen Species and Nitric Oxide in Cutaneous Leishmaniasis , 2012, Journal of parasitology research.
[10] T. Wong,et al. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials , 2012, International journal of clinical practice.
[11] K. Chayama,et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders , 2012, Hepatology.
[12] D. Pašalić,et al. Uric acid as one of the important factors in multifactorial disorders – facts and controversies , 2012, Biochemia medica.
[13] K. Diaz,et al. Oxidative Stress Response to Short Duration Bout of Submaximal Aerobic Exercise in Healthy Young Adults , 2011, International journal of exercise science.
[14] A. Craxì,et al. Hyperuricemia is associated with histological liver damage in patients with non‐alcoholic fatty liver disease , 2011, Alimentary pharmacology & therapeutics.
[15] D. Lavanchy,et al. Evolving epidemiology of hepatitis C virus. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[16] W. Gomaa,et al. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study. , 2010, Journal of gastrointestinal and liver diseases : JGLD.
[17] M. El-Ghannam,et al. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. , 2010, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[18] William M. Lee,et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.
[19] D. Dieterich,et al. Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin , 2009, Journal of viral hepatitis.
[20] G. Esmat,et al. Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis C – genotype 4 , 2009 .
[21] B. Halliwell. The wanderings of a free radical. , 2009, Free radical biology & medicine.
[22] S. Zeuzem,et al. Occult hepatitis C: How convincing are the current data? , 2009, Hepatology.
[23] B. Hunyady,et al. [Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study]. , 2009, Orvosi hetilap.
[24] M. Rizzetto,et al. Is serum uric acid a predictive factor of response to IFN‐treatment in patients with chronic hepatitis C infection? , 2008, Journal of medical virology.
[25] S. Bruno,et al. The natural course of HCV infection and the need for treatment. , 2008, Annals of hepatology.
[26] J. Murray,et al. Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations , 2007, Hepatology.
[27] F. Izzo,et al. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis , 2007, Journal of gastroenterology and hepatology.
[28] S. Kannan. Multi-drug resistance : an intrinsic or acquired phenomenon , 2006 .
[29] H. Esumi,et al. Role of nitric oxide (NO) in interferon-alpha therapy for hepatitis C. , 2005, The Journal of infection.
[30] Francesco Donato,et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.
[31] A. Folgori,et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance , 2004, Gut.
[32] N. Waugh,et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. , 2004, Health technology assessment.
[33] D. Rockey,et al. Nitric oxide biology and the liver: Report of an AASLD research workshop , 2004, Hepatology.
[34] O. Aydın,et al. Serum levels of intercellular adhesion molecule-1 and nitric oxide in patients with chronic hepatitis related to hepatitis C virus: connection fibrosis. , 2003, Hepato-gastroenterology.
[35] M. Radomski,et al. Distribution of nitric oxide synthase in normal and cirrhotic human liver , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[36] N. A. Callejas,et al. Nitric Oxide in Liver Inflammation and Regeneration , 2002, Metabolic Brain Disease.
[37] D. Sorbi,et al. Nitric Oxide and Chronic HCV and HIV Infections , 2001, Digestive Diseases and Sciences.
[38] G. Koraćević,et al. Method for the measurement of antioxidant activity in human fluids , 2001, Journal of clinical pathology.
[39] I. Young. Measurement of total antioxidant capacity , 2001, Journal of clinical pathology.
[40] B. Davidson,et al. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis , 1999, Gut.
[41] N. Ballatori,et al. Endogenous glutathione conjugates: occurrence and biological functions. , 1998, Pharmacological reviews.
[42] B. Halliwell. Free radicals, proteins and DNA: oxidative damage versus redox regulation. , 1996, Biochemical Society transactions.
[43] J. Gutteridge,et al. Lipid peroxidation and antioxidants as biomarkers of tissue damage. , 1995, Clinical chemistry.
[44] P. Jansen,et al. Nitrite and nitrate determinations in plasma: a critical evaluation. , 1995, Clinical chemistry.
[45] M. Ruiz-Larrea,et al. Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes , 1994, Steroids.
[46] G. Cohen,et al. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[47] K. Davies,et al. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. , 1986, The Biochemical journal.
[48] B. Halliwell,et al. Oxygen toxicity, oxygen radicals, transition metals and disease. , 1984, The Biochemical journal.
[49] B. Halliwell. Production of superoxide, hydrogen peroxide and hydroxyl radicals by phagocytic cells: a cause of chronic inflammatory disease? , 1982, Cell biology international reports.
[50] B. Ames,et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[51] G. Berti,et al. Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. , 1980, Clinical chemistry.
[52] G. Ellman,et al. Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.
[53] C. Piccoli,et al. Targeting mitochondria in the infection strategy of the hepatitis C virus. , 2013, The international journal of biochemistry & cell biology.
[54] R. Saller,et al. The Use of Silymarin in the Treatment of Liver Diseases , 2012, Drugs.
[55] R. Moreno-otero,et al. Pathophysiological Basis for Antioxidant Therapy in Chronic Liver Disease , 2012, Drugs.
[56] D. Harnois,et al. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .